These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1648215)

  • 21. Abnormal platelet response to thromboxane A2.
    Wu KK; Le Breton GC; Tai HH; Chen YC
    J Clin Invest; 1981 Jun; 67(6):1801-4. PubMed ID: 6263954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for the combination of anti-aggregating drugs.
    Herman AG
    Thromb Res; 1998 Sep; 92(1 Suppl 1):S17-21. PubMed ID: 9781833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
    Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
    J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
    Buerke M; Dieterich HA; Meyer J; Darius H
    Agents Actions Suppl; 1992; 37():71-7. PubMed ID: 1378692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
    Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
    Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists.
    Ishikawa Y; Ogawa A
    Thromb Res; 1991 Dec; 64(6):667-76. PubMed ID: 1665927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
    Chen XS; Zeng HW; Jiang YY; Wan WQ; Long K
    Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):338-43. PubMed ID: 1966575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theophylline inhibits platelet aggregation, prostaglandin and thromboxane production by a mechanism which is independent of cyclic AMP.
    Burns GB; Dodge JA
    Agents Actions; 1984 Jan; 14(1):102-8. PubMed ID: 6322546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
    Liao CH; Ko FN; Wu CL; Teng CM
    J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones.
    Ko FN; Sheu SJ; Liu YM; Huang TF; Teng CM
    Thromb Res; 1990 Feb; 57(3):453-63. PubMed ID: 2156351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexylamine (IBI P-05006), a thromboxane receptor antagonist.
    Rotondo S; De Gaetano G; Cerletti C
    Eur J Pharmacol; 1993 Feb; 232(1):41-5. PubMed ID: 8384563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.